--Phase 2b QUALITY clinical study topline safety data shows that the enobosarm + semaglutide combination had a positive safety profile compared to semaglutide alone-- --Based on Phase 2b QUALITY trial ...
Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced publication in The ...
Late-breaking oral presentation by a leading global authority in Dementia with Lewy bodies (DLB) to highlight updated data from Phase 2b study on ...
A 12 mg dose of BPL-003 (mebufotenin benzoate nasal spray) administered eight weeks after an initial 12 mg, 8 mg or 0.3 mg ...
Treatment of Relapsed Wilms’ Tumor With High-Dose Therapy and Autologous Hematopoietic Stem-Cell Rescue: The Experience at Children’s Memorial Hospital Interleukin-12 (IL-12) and interferon alfa-2b ...
MindBio Therapeutics Corp. announced the results of its Phase 2B clinical trial investigating the effects of microdosed LSD on Major Depressive Disorder (MDD). The trial found that microdosed LSD did ...
To assess the effects of radiation on bronchial epithelium, BEAS 2B cells cultured as monolayers and human bronchial epithelium cultured as organ cultures were exposed to single doses of 0, 10 and 30 ...
Atai Beckley (ATAI) announced topline results from the open-label extension study of its Phase 2b clinical trial of BPL-003 in patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback